{
  "question": "Patient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 157 cm,Body weight: 57 kg,BMI: 23.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 8.44,Albumin: 4.9 g/dL,Lymphocyte: 1.99,Neutrophil: 5.81,LDH level: 143.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,KRAS,MSH3,NF2,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?",
  "options": {
    "A": "Complete Response",
    "B": "Partial Response",
    "C": "Stable Disease",
    "D": "Progressive Disease"
  },
  "answer_idx": "B",
  "answer": "PR",
  "process_id": 747,
  "options_str": "A. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease",
  "gpt_filter_query": "<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 157 cm,Body weight: 57 kg,BMI: 23.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 8.44,Albumin: 4.9 g/dL,Lymphocyte: 1.99,Neutrophil: 5.81,LDH level: 143.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,KRAS,MSH3,NF2,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: PR\n</Multiple-choice Question>\n\nYou are an expert in filtering and evaluating multiple-choice questions for advanced reasoning tasks. Your job is to evaluate a given question and determine whether it meets the following criteria: \n1. **Depth of Reasoning:** The question should require deeper reasoning. If the question appears too simple, mark it as \"Too Simple\".\n2. **Unambiguous Correct Answer:** The question must have a unique and unambiguous correct answer. If the question asks for \"incorrect options\" or allows for multiple correct answers, mark it as \"Ambiguous Answer\".\n3. **Open-Ended Reformulation Feasibility:** The question should be suitable for reformatting into an open-ended format. If the question cannot be easily reformulated into an open-ended problem and a clear ground-truth answer, mark it as \"Not Reformulatable\".\n\nFor each question, provide one of the following evaluations:  \n- \"Pass\" (The question meets all the criteria.)  \n- \"Too Simple\"  \n- \"Ambiguous Answer\"  \n- \"Not Reformulatable\" ",
  "gpt_filter_response": "Pass",
  "gpt_reformat_query": "I will provide you with a multiple-choice question, and your task is to rewrite it into an open-ended question, along with a Ground-True Answer. The requirements are:\n\n1. The question must be specific, targeting the point being tested in the original multiple-choice question. Ensure it is open-ended, meaning no options are provided, but there must be a definitive Ground-True Answer.\n2. Based on the correct answer from the original question, provide a concise Ground-True Answer. The answer should allow for precise matching to determine whether the model's response is correct.\n\nHere is the multiple-choice question for you to rewrite:\n<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 58 years old,Sex: F,Height: 157 cm,Body weight: 57 kg,BMI: 23.12,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,PD-L1 group: 1~49%,PD-L1 (SP263): 5%,WBC: 8.44,Albumin: 4.9 g/dL,Lymphocyte: 1.99,Neutrophil: 5.81,LDH level: 143.0 U/L,Treatment type: Chemotherapy,Treatment regimen: Paclitaxel/Carboplatin,SNV mutations: CDKN2A,KRAS,MSH3,NF2,NKX2-1,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 5.5 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: PR\n</Multiple-choice Question>\n\nPlease output the result in the following JSON format:\n```json\n{\n\"Open-ended Verifiable Question\": \"...\",\n\"Ground-True Answer\": \"...\"\n}\n```",
  "gpt_reformat_response": "```json\n{\n    \"Open-ended Verifiable Question\": \"Based on the patient's clinical profile, including her cancer stage, PD-L1 expression, EGFR status, and treatment regimen, what is the most likely treatment response expected for her chemotherapy with Paclitaxel/Carboplatin?\",\n    \"Ground-True Answer\": \"Partial Response\"\n}\n```",
  "Open-ended Verifiable Question": "Based on the patient's clinical profile, including her cancer stage, PD-L1 expression, EGFR status, and treatment regimen, what is the most likely treatment response expected for her chemotherapy with Paclitaxel/Carboplatin?",
  "Ground-True Answer": "Partial Response",
  "verify": [
    true
  ],
  "Long_CoT": [
    {
      "action": "Inner Thinking",
      "title": "Understanding Cancer Stage",
      "content": "The patient's cancer stage provides context on the severity and spread of the disease. In general, higher stages indicate more extensive disease, which often correlates with a more challenging treatment response. For chemotherapy with Paclitaxel/Carboplatin, higher stages might mean a reduced likelihood of a complete response."
    },
    {
      "action": "Inner Thinking",
      "title": "Assessing PD-L1 Expression",
      "content": "PD-L1 expression levels can inform about the potential responsiveness to immunotherapy. Higher PD-L1 levels have been associated with better responses to immunotherapy rather than traditional chemotherapy. However, PD-L1 might still provide insight into the tumor's immune landscape, which can indirectly impact chemotherapy effectiveness."
    },
    {
      "action": "Inner Thinking",
      "title": "Evaluating EGFR Status",
      "content": "EGFR mutations, particularly in non-small cell lung cancer, might suggest potential benefit from targeted therapies over standard chemotherapy. Nevertheless, EGFR status alone might not significantly alter the expectations for chemotherapy involving Paclitaxel/Carboplatin unless targeted therapy is involved."
    },
    {
      "action": "Inner Thinking",
      "title": "Understanding Treatment Regimen",
      "content": "Paclitaxel combined with Carboplatin is a standard chemotherapy regimen used for several types of cancers, including non-small cell lung cancer. This combination is known for being generally effective but typically does not lead to cure, with the outcomes heavily influenced by individual patient factors such as tumor biology and stage."
    },
    {
      "action": "Final Conclusion",
      "content": "Based on the patient's cancer stage, PD-L1 expression, EGFR status, and treatment regimen with Paclitaxel/Carboplatin, the most likely treatment response is partial response or stable disease. Complete response is less likely but not impossible, especially if the cancer stage is lower and other favorable factors are present."
    },
    {
      "action": "Verification",
      "content": "The reasoning consistently ties together the patient's genetic status, tumor characteristics, and the chosen treatment regimen. The typical outcomes associated with Paclitaxel/Carboplatin in varied clinical scenarios were considered. The conclusion of partial response or stable disease aligns with common clinical expectations, thus holding as valid."
    }
  ],
  "gpt4_query_cot": [
    "<question>\nBased on the patient's clinical profile, including her cancer stage, PD-L1 expression, EGFR status, and treatment regimen, what is the most likely treatment response expected for her chemotherapy with Paclitaxel/Carboplatin?\n</question>\n\nPlease respond to the above question <question> using the Chain of Thought (CoT) reasoning method. Your response should consist of multiple steps, each of which includes three types of actions: **\"Inner Thinking\"**, **\"Final Conclusion\"**, and **\"Verification\"**:\n\n- **'Inner Thinking'**: This is the step where thinking is done. Note that multiple 'Inner Thinking' steps are required to describe thorough reasoning. Each step should first generate a brief title.\n- **'Final Conclusion'**: At this stage, you summarize the correct reasoning from previous 'Inner Thinking' steps and provide the final answer. No title is required here.\n- **'Verification'**: At this stage, you verify the conclusion from the \"Final Conclusion\" step. If the conclusion holds, end the process. If not, return to \"Inner Thinking\" for further reasoning. No title is required here.\n\nThe output format must strictly follow the JSON structure below:\n```json\n{\n\"CoT\": [\n    {\"action\": \"Inner Thinking\", \"title\": \"...\", \"content\": \"...\"},\n    ...,\n    {\"action\": \"Final Conclusion\", \"content\": \"...\"},\n    {\"action\": \"Verification\", \"content\": \"...\"}\n]\n}\n```",
    "<Model Response>  \nBased on the patient's cancer stage, PD-L1 expression, EGFR status, and treatment regimen with Paclitaxel/Carboplatin, the most likely treatment response is partial response or stable disease. Complete response is less likely but not impossible, especially if the cancer stage is lower and other favorable factors are present.  \n</Model Response>  \n\n<Reference Answer>  \nPartial Response\n</Reference Answer>  \n\nYou are provided with a model-generated response (<Model Response>) and a reference answer (<Reference Answer>). Compare the model response with the reference answer and determine its correctness. Your task is to simply output \"True\" if the response is correct, and \"False\" otherwise.",
    "<Thought Process>\n### Understanding Cancer Stage\nThe patient's cancer stage provides context on the severity and spread of the disease. In general, higher stages indicate more extensive disease, which often correlates with a more challenging treatment response. For chemotherapy with Paclitaxel/Carboplatin, higher stages might mean a reduced likelihood of a complete response.\n\n### Assessing PD-L1 Expression\nPD-L1 expression levels can inform about the potential responsiveness to immunotherapy. Higher PD-L1 levels have been associated with better responses to immunotherapy rather than traditional chemotherapy. However, PD-L1 might still provide insight into the tumor's immune landscape, which can indirectly impact chemotherapy effectiveness.\n\n### Evaluating EGFR Status\nEGFR mutations, particularly in non-small cell lung cancer, might suggest potential benefit from targeted therapies over standard chemotherapy. Nevertheless, EGFR status alone might not significantly alter the expectations for chemotherapy involving Paclitaxel/Carboplatin unless targeted therapy is involved.\n\n### Understanding Treatment Regimen\nPaclitaxel combined with Carboplatin is a standard chemotherapy regimen used for several types of cancers, including non-small cell lung cancer. This combination is known for being generally effective but typically does not lead to cure, with the outcomes heavily influenced by individual patient factors such as tumor biology and stage.\n\n### Conclusion\nBased on the patient's cancer stage, PD-L1 expression, EGFR status, and treatment regimen with Paclitaxel/Carboplatin, the most likely treatment response is partial response or stable disease. Complete response is less likely but not impossible, especially if the cancer stage is lower and other favorable factors are present.\n\n### Verification\nThe reasoning consistently ties together the patient's genetic status, tumor characteristics, and the chosen treatment regimen. The typical outcomes associated with Paclitaxel/Carboplatin in varied clinical scenarios were considered. The conclusion of partial response or stable disease aligns with common clinical expectations, thus holding as valid.\n</Thought Process>\n\n<Question>\nBased on the patient's clinical profile, including her cancer stage, PD-L1 expression, EGFR status, and treatment regimen, what is the most likely treatment response expected for her chemotherapy with Paclitaxel/Carboplatin?\n</Question>\n\nThe <Thought Process> above reflects the model's reasoning based on the <Question>. Your task is to rewrite the <Thought Process> to resemble a more human-like, intuitive natural thinking process. The new version should:\n\n1. Be presented as step-by-step reasoning, with each thought on a new line separated by a line break.\n2. Avoid structured titles or formatting, focusing on natural transitions. Use casual and natural language for transitions or validations, such as \"hmm,\" \"oh,\" \"also,\" or \"wait.\"\n3. Expand the content, making the reasoning richer, more detailed, and logically clear while still being conversational and intuitive.\n\nReturn directly the revised natural thinking in JSON format as follows:\n```json\n{\n  \"NaturalReasoning\": \"...\"\n}\n```",
    "<Internal Thinking>\nOkay, first things first, let's think about what the stage of the cancer means for treatment. The stage gives us an idea of how far the cancer has spread, right? So, the higher the stage, the more severe it seems, which usually makes it tougher to treat. For the Paclitaxel and Carboplatin combo, if we're talking about a higher stage, we're likely looking at a lower chance for a complete response.\n\nNow, moving on to PD-L1 expression. This is one of those biomarkers that can tell us how the cancer might react to immunotherapy. Generally, the higher the PD-L1, the better the response to immunotherapy or so they say. But even if we're not using immunotherapy here, the PD-L1 levels might still give us a peek into how the tumor interacts with the immune system, which might, in turn, affect how well chemotherapy could work.\n\nOh, and then there's EGFR status. When we see mutations here, especially in things like non-small cell lung cancer, it often points to a possible advantage from targeted therapies as opposed to the old-school chemotherapy approach. But unless we're dealing with targeted therapies, EGFR status might not drastically change what we expect from Paclitaxel and Carboplatin.\n\nSpeaking of which, this combo—Paclitaxel and Carboplatin—is pretty much a staple treatment for a bunch of cancers, including non-small cell lung cancer. It's known to be fairly effective, generally speaking. But let's face it, it rarely results in a cure, especially when we're looking at individual factors like tumor biology or the stage.\n\nSo putting it all together, considering the stage of cancer, the PD-L1 expression, the EGFR status, and knowing we're going with Paclitaxel and Carboplatin, I'd say we're probably going to see something like a partial response or maybe the disease stays stable. A complete response could happen but seems like a long shot unless maybe the cancer stage is on the lower end and there's a nicer mix of factors.\n\nWhen I think about all this, it ties back to how we understand what typically happens with this treatment regimen in different clinical contexts. The conclusion seems solidly in the ballpark of a partial response or stable disease, which aligns with what's commonly expected. That feels like a pretty reasonable and practical outlook.\n</Internal Thinking>\n\n<Question>\nBased on the patient's clinical profile, including her cancer stage, PD-L1 expression, EGFR status, and treatment regimen, what is the most likely treatment response expected for her chemotherapy with Paclitaxel/Carboplatin?\n</Question>\n\nThe <Internal Thinking> represents your internal thoughts about the <Question>. Based on this, generate a rich and high-quality final response to the user. If there is a clear answer, provide it first. Ensure your final response closely follows the <Question>. The response style should resemble GPT-4's style as much as possible. Output only your final response, without any additional content."
  ],
  "gpt4_response_cot": [
    "```json\n{\n    \"CoT\": [\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Understanding Cancer Stage\",\n            \"content\": \"The patient's cancer stage provides context on the severity and spread of the disease. In general, higher stages indicate more extensive disease, which often correlates with a more challenging treatment response. For chemotherapy with Paclitaxel/Carboplatin, higher stages might mean a reduced likelihood of a complete response.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Assessing PD-L1 Expression\",\n            \"content\": \"PD-L1 expression levels can inform about the potential responsiveness to immunotherapy. Higher PD-L1 levels have been associated with better responses to immunotherapy rather than traditional chemotherapy. However, PD-L1 might still provide insight into the tumor's immune landscape, which can indirectly impact chemotherapy effectiveness.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Evaluating EGFR Status\",\n            \"content\": \"EGFR mutations, particularly in non-small cell lung cancer, might suggest potential benefit from targeted therapies over standard chemotherapy. Nevertheless, EGFR status alone might not significantly alter the expectations for chemotherapy involving Paclitaxel/Carboplatin unless targeted therapy is involved.\"\n        },\n        {\n            \"action\": \"Inner Thinking\",\n            \"title\": \"Understanding Treatment Regimen\",\n            \"content\": \"Paclitaxel combined with Carboplatin is a standard chemotherapy regimen used for several types of cancers, including non-small cell lung cancer. This combination is known for being generally effective but typically does not lead to cure, with the outcomes heavily influenced by individual patient factors such as tumor biology and stage.\"\n        },\n        {\n            \"action\": \"Final Conclusion\",\n            \"content\": \"Based on the patient's cancer stage, PD-L1 expression, EGFR status, and treatment regimen with Paclitaxel/Carboplatin, the most likely treatment response is partial response or stable disease. Complete response is less likely but not impossible, especially if the cancer stage is lower and other favorable factors are present.\"\n        },\n        {\n            \"action\": \"Verification\",\n            \"content\": \"The reasoning consistently ties together the patient's genetic status, tumor characteristics, and the chosen treatment regimen. The typical outcomes associated with Paclitaxel/Carboplatin in varied clinical scenarios were considered. The conclusion of partial response or stable disease aligns with common clinical expectations, thus holding as valid.\"\n        }\n    ]\n}\n```",
    "True",
    "```json\n{\n  \"NaturalReasoning\": \"Okay, first things first, let's think about what the stage of the cancer means for treatment. The stage gives us an idea of how far the cancer has spread, right? So, the higher the stage, the more severe it seems, which usually makes it tougher to treat. For the Paclitaxel and Carboplatin combo, if we're talking about a higher stage, we're likely looking at a lower chance for a complete response.\\n\\nNow, moving on to PD-L1 expression. This is one of those biomarkers that can tell us how the cancer might react to immunotherapy. Generally, the higher the PD-L1, the better the response to immunotherapy or so they say. But even if we're not using immunotherapy here, the PD-L1 levels might still give us a peek into how the tumor interacts with the immune system, which might, in turn, affect how well chemotherapy could work.\\n\\nOh, and then there's EGFR status. When we see mutations here, especially in things like non-small cell lung cancer, it often points to a possible advantage from targeted therapies as opposed to the old-school chemotherapy approach. But unless we're dealing with targeted therapies, EGFR status might not drastically change what we expect from Paclitaxel and Carboplatin.\\n\\nSpeaking of which, this combo—Paclitaxel and Carboplatin—is pretty much a staple treatment for a bunch of cancers, including non-small cell lung cancer. It's known to be fairly effective, generally speaking. But let's face it, it rarely results in a cure, especially when we're looking at individual factors like tumor biology or the stage.\\n\\nSo putting it all together, considering the stage of cancer, the PD-L1 expression, the EGFR status, and knowing we're going with Paclitaxel and Carboplatin, I'd say we're probably going to see something like a partial response or maybe the disease stays stable. A complete response could happen but seems like a long shot unless maybe the cancer stage is on the lower end and there's a nicer mix of factors.\\n\\nWhen I think about all this, it ties back to how we understand what typically happens with this treatment regimen in different clinical contexts. The conclusion seems solidly in the ballpark of a partial response or stable disease, which aligns with what's commonly expected. That feels like a pretty reasonable and practical outlook.\"\n}\n```",
    "Based on the provided clinical profile, the most likely treatment response expected for the patient receiving chemotherapy with Paclitaxel and Carboplatin is a partial response or stable disease. This expectation takes into account the cancer stage, which typically correlates with more advanced disease being less responsive to chemotherapy alone, and the known efficacy of the regimen. While PD-L1 expression and EGFR status provide insights into potential outcomes with targeted therapies and immunotherapies, they have less direct implications for the effectiveness of this specific chemotherapy regimen. Overall, while a complete response is possible, it is less likely, making a partial response or stable disease the more realistic expectation for this treatment scenario."
  ],
  "response_struct": [
    [
      {
        "action": "Inner Thinking",
        "title": "Understanding Cancer Stage",
        "content": "The patient's cancer stage provides context on the severity and spread of the disease. In general, higher stages indicate more extensive disease, which often correlates with a more challenging treatment response. For chemotherapy with Paclitaxel/Carboplatin, higher stages might mean a reduced likelihood of a complete response."
      },
      {
        "action": "Inner Thinking",
        "title": "Assessing PD-L1 Expression",
        "content": "PD-L1 expression levels can inform about the potential responsiveness to immunotherapy. Higher PD-L1 levels have been associated with better responses to immunotherapy rather than traditional chemotherapy. However, PD-L1 might still provide insight into the tumor's immune landscape, which can indirectly impact chemotherapy effectiveness."
      },
      {
        "action": "Inner Thinking",
        "title": "Evaluating EGFR Status",
        "content": "EGFR mutations, particularly in non-small cell lung cancer, might suggest potential benefit from targeted therapies over standard chemotherapy. Nevertheless, EGFR status alone might not significantly alter the expectations for chemotherapy involving Paclitaxel/Carboplatin unless targeted therapy is involved."
      },
      {
        "action": "Inner Thinking",
        "title": "Understanding Treatment Regimen",
        "content": "Paclitaxel combined with Carboplatin is a standard chemotherapy regimen used for several types of cancers, including non-small cell lung cancer. This combination is known for being generally effective but typically does not lead to cure, with the outcomes heavily influenced by individual patient factors such as tumor biology and stage."
      },
      {
        "action": "Final Conclusion",
        "content": "Based on the patient's cancer stage, PD-L1 expression, EGFR status, and treatment regimen with Paclitaxel/Carboplatin, the most likely treatment response is partial response or stable disease. Complete response is less likely but not impossible, especially if the cancer stage is lower and other favorable factors are present."
      },
      {
        "action": "Verification",
        "content": "The reasoning consistently ties together the patient's genetic status, tumor characteristics, and the chosen treatment regimen. The typical outcomes associated with Paclitaxel/Carboplatin in varied clinical scenarios were considered. The conclusion of partial response or stable disease aligns with common clinical expectations, thus holding as valid."
      }
    ]
  ],
  "response_type": [
    "Init_CoT"
  ],
  "prior_fail_try": [],
  "Complex_CoT": "Okay, first things first, let's think about what the stage of the cancer means for treatment. The stage gives us an idea of how far the cancer has spread, right? So, the higher the stage, the more severe it seems, which usually makes it tougher to treat. For the Paclitaxel and Carboplatin combo, if we're talking about a higher stage, we're likely looking at a lower chance for a complete response.\n\nNow, moving on to PD-L1 expression. This is one of those biomarkers that can tell us how the cancer might react to immunotherapy. Generally, the higher the PD-L1, the better the response to immunotherapy or so they say. But even if we're not using immunotherapy here, the PD-L1 levels might still give us a peek into how the tumor interacts with the immune system, which might, in turn, affect how well chemotherapy could work.\n\nOh, and then there's EGFR status. When we see mutations here, especially in things like non-small cell lung cancer, it often points to a possible advantage from targeted therapies as opposed to the old-school chemotherapy approach. But unless we're dealing with targeted therapies, EGFR status might not drastically change what we expect from Paclitaxel and Carboplatin.\n\nSpeaking of which, this combo—Paclitaxel and Carboplatin—is pretty much a staple treatment for a bunch of cancers, including non-small cell lung cancer. It's known to be fairly effective, generally speaking. But let's face it, it rarely results in a cure, especially when we're looking at individual factors like tumor biology or the stage.\n\nSo putting it all together, considering the stage of cancer, the PD-L1 expression, the EGFR status, and knowing we're going with Paclitaxel and Carboplatin, I'd say we're probably going to see something like a partial response or maybe the disease stays stable. A complete response could happen but seems like a long shot unless maybe the cancer stage is on the lower end and there's a nicer mix of factors.\n\nWhen I think about all this, it ties back to how we understand what typically happens with this treatment regimen in different clinical contexts. The conclusion seems solidly in the ballpark of a partial response or stable disease, which aligns with what's commonly expected. That feels like a pretty reasonable and practical outlook.",
  "Response": "Based on the provided clinical profile, the most likely treatment response expected for the patient receiving chemotherapy with Paclitaxel and Carboplatin is a partial response or stable disease. This expectation takes into account the cancer stage, which typically correlates with more advanced disease being less responsive to chemotherapy alone, and the known efficacy of the regimen. While PD-L1 expression and EGFR status provide insights into potential outcomes with targeted therapies and immunotherapies, they have less direct implications for the effectiveness of this specific chemotherapy regimen. Overall, while a complete response is possible, it is less likely, making a partial response or stable disease the more realistic expectation for this treatment scenario.",
  "Question": "Based on the patient's clinical profile, including her cancer stage, PD-L1 expression, EGFR status, and treatment regimen, what is the most likely treatment response expected for her chemotherapy with Paclitaxel/Carboplatin?"
}